FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer

Retention of androgen receptor (AR) signalling in castrate-resistant prostate cancer (CRPC) highlights the requirement for the development of more effective AR targeting therapies. A key mechanism of resistance to anti-androgens is through expression of constitutively active AR variants (AR-Vs) that...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Dominic, Wade, Mark, Nakjang, Sirintra, Chaytor, Lewis, Grey, James, Robson, Craig N., Gaughan, Luke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745762/
https://www.ncbi.nlm.nih.gov/pubmed/26336819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745762/
https://www.ncbi.nlm.nih.gov/pubmed/26336819

Ejemplares similares